DE4432947A1 - Skin-treating agent contg. isoflavone or deriv. - Google Patents

Skin-treating agent contg. isoflavone or deriv.

Info

Publication number
DE4432947A1
DE4432947A1 DE4432947A DE4432947A DE4432947A1 DE 4432947 A1 DE4432947 A1 DE 4432947A1 DE 4432947 A DE4432947 A DE 4432947A DE 4432947 A DE4432947 A DE 4432947A DE 4432947 A1 DE4432947 A1 DE 4432947A1
Authority
DE
Germany
Prior art keywords
isoflavone
composition according
active ingredient
weight
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE4432947A
Other languages
German (de)
Other versions
DE4432947C2 (en
Inventor
Reinhold A Dr Brunke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEW STANDARD GmbH
Original Assignee
NEW STANDARD GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6528338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE4432947(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NEW STANDARD GmbH filed Critical NEW STANDARD GmbH
Priority to DE4432947A priority Critical patent/DE4432947C2/en
Publication of DE4432947A1 publication Critical patent/DE4432947A1/en
Application granted granted Critical
Publication of DE4432947C2 publication Critical patent/DE4432947C2/en
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Abstract

Agent for treating the skin contains isoflavone (I) or derivs. Pref. the deriv. is a glycoside, ether, ester or acetal; or an acid, salt, quinone or acetal derived from isoflavone. (I) is pref. 4-hydroxy-7-glucose-isoflavone, 5,7,4'-tri:hydroxy isoflavone, 5,4'-dihydroxy-7-glucose- isoflavone, 5-hydroxy-7,4'-dimethoxy-isoflavone, 7,4'-dihydroxy-isoflavone, 5,7-dihydroxy-4'-methoxy-isoflavone, 3',4',5,7-tetrahydroxy-isoflavone, 3',4',5-tri:hydroxy-7- methoxy-isoflavone, 3',5,7-trihydroxy-4'-isoflavone or 3',5,7-trihydroxy-4',5',6-trimethoxy-isoflavone. Pref. the agent contains at least 0.005 wt.% (I) (or its derivs.), pref. 0.005-0.1 wt.%. The agent pref. also contains sterol cpds.

Description

Die vorliegende Erfindung betrifft ein neuartiges Mittel zur Behandlung der Haut, insbesondere zur kosmetischen oder medizinischen Anwendung.The present invention relates to a novel skin treatment agent, in particular for cosmetic or medical use.

Zur Pflege und Behandlung der Haut werden auf dem Markt zahlreiche Produkte angeboten. Es handelt sich hierbei im wesentlichen um Lotionen, Milche, Cremes und Pasten.For the care and treatment of the skin are on the market numerous products offered. These are essentially lotions, milks, creams and Pastes.

Die angebotenen Reinigungslotionen, -milche, -cremes und -pasten basieren zumeist auf Öl-/Wasseremulsionen mit relativ geringen Gehalten an Fettkomponenten mit reinigenden und pflegenden Zusätzen. Die angebotene breite Palette verschiedener Hautreinigungsprodukte variiert in Zusammensetzung und Gehalt an diversen Wirkstoffen, abgestimmt auf die verschiedenen Hauttypen und spezielle Behandlungsziele.The offered cleaning lotions, -milche, -cremes and pastes are mostly based on oil / water emulsions with relatively low levels of fat components with cleansing and nourishing additives. The offered wide range of different Skin cleansing products vary in composition and content of various Active ingredients, tailored to the different skin types and special Treatment goals.

Die der Reinigung folgende Hautpflege hat zwei wesentliche Ziele: Zum einen soll sie der Haut die bei der Wäsche unkontrolliert entzogenen Inhaltsstoffe wie Hornzellen, Hautfettlipide, Säurebildner und Wasser zurückführen in den natürlichen Gleichgewichtszustand. Zum anderen sollen sie den natürlichen Alterungsprozeß der Haut sowie den möglichen Schädigungen durch Witterungs- und Umwelteinflüsse weitgehend entgegenwirken. Präparate zur Hautpflege und zum Hautschutz werden in großer Zahl und in vielen Zubereitungsformen angeboten. Die wichtigsten sind Hautcremes, -lotionen, -öle und -gele. Basis der Cremes und Lotionen sind Emulsionen Öl in Wasser oder Wasser in Öl-Form. Die Hauptbestandteile der Öl­ bzw. Fett- oder Lipid-Phase sind Fettalkohole, Fettsäuren, Fettsäureester, Wachse, Vaseline, Paraffine sowie weitere Fett- und Ölkomponenten hauptsächlich natürlichen Ursprungs. In der wäßrigen Phase sind neben Wasser hauptsächlich feuchtigkeitsregulierende und feuchtigkeitsbewahrende Substanzen als wesentlicher Hautpflege-Wirkstoff enthalten, ferner konsistenz- bzw. viskositätsregulierende Mittel. Weitere Zusätze wie Konservierungsmittel, Antioxidanzien, Komplexbildner, Parfüm- Öle, Färbemittel sowie spezielle Wirkstoffe werden je nach ihrer Löslichkeit und ihren Stabilitätseigenschaften einer der beiden vorgenannten Phasen beigegeben.The following skincare has two main goals: First, it should the skin the ingredients unchecked during washing, such as horny cells, Skin fat lipids, acidifiers and water traceable in the natural Equilibrium. On the other hand, they should the natural aging process of  Skin as well as possible damage from weather and environmental influences largely counteract. Skin care and skin protection preparations offered in large numbers and in many forms of preparation. The most important are Skin creams, lotions, oils and gels. Basis of the creams and lotions are Emulsions Oil in water or water in oil form. The main components of the oil fat or lipid phase are fatty alcohols, fatty acids, fatty acid esters, waxes, Vaseline, paraffins as well as other fat and oil components mainly natural Origin. In the aqueous phase, water is the main one moisture-regulating and moisture-retaining substances as essential Skincare active ingredient, further consistency or viscosity regulating agents. Other additives such as preservatives, antioxidants, complexing agents, perfume Oils, colorants as well as special active substances are depending on their solubility and their Stability properties added to one of the two aforementioned phases.

Hautöle gehören zu den ältesten Produkten der Hautpflege und werden heute noch verwendet. Basis sind nicht trocknende Pflanzenöle, wie Mandelöl oder Olivenöl mit Zusätzen natürlicher Vitaminöle wie Weizenkeimöl oder Avokadoöl sowie öligen Pflanzenextrakten, z. B. Johanniskraut, Kamille und ähnlichen. Der Zusatz von Antioxidanzien gegen Ranzigkeit ist unerläßlich. Gewünschte Duftnoten werden durch Parfüm oder etherische Öle erzielt. Ein Zusatz von Paraffinöl oder flüssigen Fettsäureestern dient zur Optimierung der Anwendungseigenschaften.Skin oils are among the oldest skin care products and are still used today used. Base are non-drying vegetable oils, such as almond oil or olive oil with Additions of natural vitamin oils such as wheat germ oil or avocado oil and oily Plant extracts, eg. As St. John's wort, chamomile and the like. The addition of Antioxidants against rancidity is essential. Desired fragrance notes will be achieved by perfume or essential oils. An addition of paraffin oil or liquid Fatty acid esters serve to optimize the application properties.

Hautgele sind halbfeste transparente Produkte, die durch entsprechende Gelbbildner stabilisiert werden. Man unterscheidet Oleogele, Hydrogele und Öl/Wasser-Gele. Die Typenauswahl richtet sich nach dem gewünschten Anwendungszweck. Die Öl/Wasser-Gele enthalten hohe Emulgator-Anteile und weisen gegenüber Emulsionen gewissen Vorteile auf.Skin gels are semi-solid transparent products that are made by appropriate yellowing agents be stabilized. A distinction is made between oleogels, hydrogels and oil / water gels. The Type selection depends on the desired application. The Oil / water gels contain high emulsifier levels and face Emulsions have certain advantages.

Zu den kosmetischen Mitteln gehören auch die Haarbehandlungsmittel. Denn die Haarpflege umfaßt die Reinigung von Kopfhaut und Kopfhaar gleichermaßen. Demzufolge enthalten die Haarpflegeprodukte hautpflegende Wirkstoffe. Cosmetic products also include hair treatment products. Because the Hair care includes the cleansing of scalp and hair as well. Consequently, the hair care products contain skin care agents.  

Nachteilig bei den genannten kosmetischen Mitteln ist die Begrenzung der Wirksamkeit.A disadvantage of the mentioned cosmetic products is the limitation of Effectiveness.

Die vorliegende Erfindung hat sich nunmehr die Aufgabe gestellt, ein Mittel zur Behandlung der Haut zur Verfügung zu stellen, das für die genannten Anwendungsgebiete einen wirksamen Wirkstoffkomplex aufweist.The present invention has now taken on the task of a means for To provide treatment of the skin, that for the mentioned Areas of application has an active ingredient complex.

Diese Aufgabe wird dadurch gelöst, daß das Mittel als Wirkstoff Isoflavon enthält.This object is achieved in that the agent contains isoflavone as an active ingredient.

Bei dem erfindungsgemäßen Isoflavon handelt es sich um die meist zu den Flavonoiden gezählte, gelegentlich auch als Isoflavonoide bezeichnete Gruppe von Stoffen, die sich von 3-Phenyl-4 H-1-bezonpyran-4-on der folgenden Strukturformel ableiten:In the isoflavone according to the invention are the most to the Flavonoids counted, sometimes referred to as isoflavonoids group of Substances differing from 3-phenyl-4H-1-bezonpyran-4-one of the following structural formula derived:

Bevorzugt werden erfindungsgemäß 4 Hydroxy-7 Glucose-Isoflavon (Daidzin), 5,7,4′Trihydroxy-Isoflavon (Genistein), 5,4′Dihydroxy, 7 Glucose-Isoflavon (Genistin), 7,4′Dihydroxy-Isoflavon (Daidzein), 5,7 Dihydroxy, 4′methoxy-Isoflavon (Biochanin A), 3′,4,′5,7-Tetrahydroxyisoflavon (Orobol), 3′,4′,5-Trihydroxy-7-methoxyisoflavon (Santal), 3′,5,7-Trihydroxy-4′-methoxyisoflavon (Pratensein), 3′,5,7-Trihydroxy- 4′,5′,6-trimethoxyisoflavon (Iridin). According to the invention, preference is given to 4-hydroxy-7-glucose isoflavone (daidzin), 5,7,4'trihydroxy-isoflavone (genistein), 5,4'-dihydroxy, 7-glucose isoflavone (genistin), 7,4'-dihydroxy-isoflavone (daidzein), 5,7-dihydroxy, 4'-methoxy-isoflavone (biochanin A), 3 ', 4', 5,7-tetrahydroxyisoflavone (Orobol), 3 ', 4', 5-trihydroxy-7-methoxyisoflavone (Santal), 3 ', 5,7-trihydroxy-4'-methoxyisoflavone (pratense), 3', 5,7-trihydroxy- 4 ', 5', 6-trimethoxyisoflavone (iridine).  

Daneben kommen auch die Abkömmlinge des Isoflavons in Betracht, z. B. die in C-2 und C-3-Stellung hydrierten Isoflavone. Ebenso können sämtliche Isoflavonderivate erfindungsgemäß zum Einsatz kommen. Hierzu zählen vor allem Glykoside, Ether, Ester und von den Isoflavonen abgeleitete Säuren.In addition, the descendants of isoflavone into consideration, z. As in C-2 and C-3 position hydrogenated isoflavones. Likewise, all isoflavone derivatives used according to the invention. These include, in particular, glycosides, ethers, Esters and acids derived from isoflavones.

Die erfindungsgemäßen Wirkstoffe werden vorzugsweise in Konzentrationen von 0,1 bis 0,005 Gew.-% eingesetzt. Hierbei können in dem Mittel zusätzlich Sterole enthalten sein.The active compounds according to the invention are preferably used in concentrations of 0.1 used to 0.005 wt .-%. In addition, sterols may be added to the agent be included.

Aus der jüngsten Literatur ist die medizinische Anwendung von Isoflavonoiden zwar bekannt. Doch handelt es sich hierbei im wesentlichen um Forschungen auf dem Gebiet der Krebsvorsorge. Diese basierten auf der Erkenntnis, daß es in der Tumorrate bei Europäern und Asiaten, insbesondere im Bereich von Prostataerkrankungen und Brustkrebs signifikante Unterschiede gibt. Hierbei war man darauf gestoßen, daß der hohe Anteil an Sojaprodukten in der asiatischen Ernährung eine Ursache zu sein scheint. Im Rahmen der weiteren Arbeiten wurden sodann die Isoflavonoide als Wirkstoffe aus den Sojaprodukten isoliert und auf ihre krebshemmenden Wirkungen hin untersucht.From the recent literature, the medical use of isoflavonoids is indeed known. But this is essentially research on the Area of cancer screening. These were based on the knowledge that it was in the Tumor rate in Europeans and Asians, especially in the area of Prostate and breast cancer are significant differences. This was one it struck that the high proportion of soy products in the Asian diet a cause seems to be. As part of the further work were then the Isoflavonoids as active ingredients isolated from the soy products and theirs anticancer effects.

Ein Hinweis auf die erfindungsgemäß überraschend breiten Anwendungsbereiche findet sich jedoch in diesen Forschungsarbeiten nicht. Ebenso war es bei den bisherigen Kosmetika und medizinischen Mitteln zur Behandlung der Haut nicht bekannt, die erfindungsgemäß breite Wirkungspalette unter Einsatz nur eines einzigen Wirkstoffes zu erreichen. Denn das neue Mittel eignet sich zur Minderung der Gefäßneubildung (Couperose), der Behandlung erweiterter Venen (Besenreisern), Akne, Fetthaut, ergrauten Haaren und Pigmentflecken. Insgesamt wirkt das neue Mittel antiproliferativ bei Melanomen, Alopecie, Akne und im Haarbulbus. Darüber hinaus kann mit dem erfindungsgemäßen Mittel der Hautalterung vorgebeugt werden, da Untersuchungen ergeben haben, daß es auch als Radikalfänger wirkt.An indication of the inventively surprisingly wide application areas However, this is not found in this research. It was the same with the Previous cosmetics and medical products for the treatment of the skin did not known, the present invention wide range of effects using only one to achieve single active ingredient. Because the new agent is suitable for the reduction neovascularization (couperose), the treatment of enlarged veins (spider veins), Acne, greasy skin, graying hair and pigmentation. Overall, the new works Antiproliferative drug for melanoma, alopecia, acne and hair bulb. About that In addition, with the agent according to the invention, skin aging can be prevented, since investigations have shown that it acts as a radical scavenger.

Die erfindungsgemäß eingesetzten Isoflavone lassen sich aus Zuckerfraktionen von Pflanzen (Obst, Getreide, Gemüse, Bohnen, Kirschen, Weizen, Hafer, Soja, Erbsen, Linsen, Möhren, Pfirsiche, Kohl, Peranja-Wurzel) oder Mikroorganismen (Pseudoomas) gewinnen. Hierbei können die Isoflavone in reiner Form isoliert werden und direkt als Wirkstoff in das Mittel eingegeben werden. The isoflavones used according to the invention can be prepared from sugar fractions of Plants (fruits, cereals, vegetables, beans, cherries, wheat, oats, soybeans, peas, Lentils, carrots, peaches, cabbage, peranja root) or microorganisms (Pseudoomas) win. In this case, the isoflavones can be isolated in pure form and be entered directly into the agent as an active ingredient.  

Ebenso ist es aber auch möglich, Isoflavone synthetisch herzustellen und für die erfindungsgemäßen Zwecke einzusetzen.Likewise, it is also possible to synthetically produce isoflavones and for the Use according to the invention purposes.

Schließlich können auch ethanolische, wäßrige Extrakte aus Pflanzen, Mikroorganismen oder synthetischen Gemischen zum Einsatz kommen. Hierbei liegt der Ethanolgehalt vorzugsweise zwischen 100 und 60 Gew.-%.Finally, ethanolic, aqueous extracts of plants, Microorganisms or synthetic mixtures are used. This is the ethanol content preferably between 100 and 60 wt .-%.

Auch ist es denkbar, Hydrolyseprodukte aus Pflanzen oder Mikroorganismen bzw. deren Zuckerfraktionen oder den Extrakten der Pflanzen, Mikroorganismen und Synthesegemische herzustellen.It is also conceivable, hydrolysis products of plants or microorganisms or their sugar fractions or extracts of plants, microorganisms and Produce synthesis mixtures.

Im folgenden wird die Erfindung unter Bezugnahme auf die Beispiele näher beschrieben.In the following the invention with reference to the examples will be closer described.

Beispiel 1example 1

Um die Minderung von Blutgefäß-Neubildungen nachzuweisen, wurden die Rezepturen 2 und 3 täglich dreimal auf die entsprechenden Zonen aufgetragen. Ebenso wurde der Einsatz als Radikalfänger und Pigmentflecken-Minderer nachgewiesen. Die Kontrolle nach 8 Wochen ergab jeweils eine leichte Minderung der Blutgefäß-Neubildungen und der Pigmentflecken.To demonstrate the reduction of new blood vessel neoplasms, the Apply recipes 2 and 3 daily to the appropriate zones three times. Likewise, the use as radical scavenger and pigment spot reducer demonstrated. The control after 8 weeks showed a slight reduction in each case Blood vessel neoplasms and the pigmentation spots.

Beispiel 2Example 2

Die Proliferationsrate-Senkung wurde im Falle von Sebumproduktion Haarwuchs und Hyperkeratinisierung bei Akne geprüft. Dazu wurden die Rezepturen 1 und 2 eingesetzt. Bei der Anwendung der Rezeptur 1 wurde täglich mehrmals auf die entsprechenden Areale mit Hilfe eines handelsüblichen Pumpspray-Fläschchens appliziert; im Falle der Rezeptur 2 wurde dünn auf die entsprechenden Hautareale aufgetragen.The rate of proliferation was reduced in the case of sebum production and hair growth Hyperkeratinization checked for acne. These were the recipes 1 and 2 used. When applying the formula 1 was added several times daily to the corresponding areas with the help of a commercially available pump spray vial applied; in the case of the recipe 2 was thin on the appropriate skin areas applied.

Als Ergebnis wurde folgendes festgestellt:
Minderung des Aknegradings nach 15 Tagen und Minderung der Fetthaut nach 4 Wochen. Die Haarwuchsrate konnte erst nach 2 Monaten kontrolliert werden (Messung des Wuchses in 2 Monaten) und zeigte eine minimale Erniedrigung. As a result, the following was found:
Reduction of the acne grading after 15 days and reduction of the greasy skin after 4 weeks. The hair growth rate could be controlled only after 2 months (measurement of growth in 2 months) and showed a minimal reduction.

Beispiel 3Example 3

Die Grauhaar-Minderung und haarwuchsregulierende Wirkung bei androgenetischer Alopecie wurden mit dem Spray gemäß Rezeptur 5 erprobt. Es wurde nach Monaten eine geringe Ausfallquote bemerkt (Verlängerung der Anagenphase), was den Einfluß auf der Ebene der hormonellen Regulation ohne Hormoneinsatz beweist.The gray-hair reduction and hair-growth-regulating effect in androgenetic Alopecia were tested with the spray according to recipe 5. It was months later noted a low failure rate (prolonging the anagen phase), which is the influence at the level of hormonal regulation without hormone use.

Rezept 1: Spray, Ampullen-FlüssigkeitRecipe 1: Spray, Ampoule Liquid Wasser dem.Water that. 7 Gew.-%7% by weight Ethanol denat.Ethanol denate. 83 Gew.-%83% by weight Sojaextrakt GSoya extract G 10 Gew.-%10% by weight

Rezept 2: Isoflavon-GelRecipe 2: Isoflavone gel Phase 1:Phase 1: Eumulgin B1Eumulgin B1 3 Gew.-%3% by weight Cetiol 868Cetiol 868 10 Gew.-%10% by weight Methylparabenmethylparaben 0,15 Gew.-%0.15% by weight ProphyarabenProphyaraben 0,10 Gew.-%0.10% by weight Sojaextrakt GSoya extract G 10,0 Gew.-%10.0% by weight Phase 2: @Phase 2: @ Wasserwater 73 Gew.-%73% by weight Phase 3: @Phase 3: @ Sepigel 305Sepigel 305 3,5 Gew.-%3.5% by weight Phase 4: @Phase 4: @ Kathon CGKathon CG 0,05 Gew.-%0.05% by weight

HerstellungsvorschriftPreparation Method

Phase 1 wird bei ca. 60 Grad aufgeschmolzen. Phase 2 wird auf ca. 60 Grad erwärmt. Danach werden beide Phasen zusammengegeben und verrührt. Anschließend wird Phase 3 zugegeben und bis zum Gelzustand blasenfrei verrührt. Schließlich wird nach Abkühlung auf ca. 30 Grad Phase 4 zugesetzt.Phase 1 is melted at about 60 degrees. Phase 2 is heated to about 60 degrees. Then both phases are combined and mixed. Subsequently, will Phase 3 added and stirred bubble-free until gel state. Finally will after cooling to about 30 degrees, phase 4 is added.

Rezept 3: Isoflavon-LotionRecipe 3: Isoflavone lotion Phase 1:Phase 1: Eumulgin B2Eumulgin B2 3,5 Gew.-%3.5% by weight Cutina MDCutina MD 5 Gew.-%5% by weight Cetiol 868Cetiol 868 7 Gew.-%7% by weight Jojobaöljojoba oil 3 Gew.-%3% by weight Methylparabenmethylparaben 0,15 Gew.-%0.15% by weight PropylparabenPropylparaben 0,10 Gew.-%0.10% by weight Sojaextrakt GSoya extract G 10 Gew.-%10% by weight Phase 2: @Phase 2: @ Wasserwater 70,5 Gew.-%70.5% by weight Carbapol934Carbapol934 0,30 Gew.-%0.30% by weight Phase 3: @Phase 3: @ Kathon CGKathon CG 0,05 Gew.-%0.05% by weight Triethanolamintriethanolamine 0,45 Gew.-%0.45% by weight

Rezept 4: Isoflavon-CremeRecipe 4: Isoflavone cream Phase 1:Phase 1: DiglycerindiisostearatDiglycerindiisostearat 4 Gew.-%4% by weight Vaseline 4814Vaseline 4814 10 Gew.-%10% by weight Paraffinöl P 1500Paraffin oil P 1500 5 Gew.-%5% by weight Lunacera MLunacera M 1,0 Gew.-%1.0% by weight Cetiol 868Cetiol 868 5,0 Gew.-% 5.0% by weight   Methylparabenmethylparaben 0,15 Gew.-%0.15% by weight PropylparabenPropylparaben 0,10 Gew.-%0.10% by weight Sojaextrakt GSoya extract G 10 Gew.-%10% by weight Phase 2: @Phase 2: @ Wasserwater 64,3 Gew.-%64.3% by weight Magnesiumsulfatmagnesium sulfate 0,40 Gew.-%0.40% by weight Phase 3: @Phase 3: @ Kathon CGKathon CG 0,050 Gew.-%0.050% by weight

Herstellungsvorschrift für Rezept 3 und 4Manufacturing instructions for Recipe 3 and 4

Phase 1 und 2 werden separat auf 70 Grad erwärmt und danach zusammengegeben. Bis zur Abkühlung auf 35 Grad wird gerührt. Schließlich wird Phase 3 unter Rühren zugegeben.Phase 1 and 2 are heated separately to 70 degrees and then combined. Stir until cool to 35 degrees. Finally will Phase 3 added with stirring.

Rezept 5: Haarwuchs-SprayRecipe 5: Hair Growth Spray Ethanol denat.Ethanol denate. 88 Gew.-%88% by weight Calcium-SuccinatCalcium succinate 1 Gew.-%1% by weight N-AcetylcysteinN-acetylcysteine 0,5 Gew.-%0.5% by weight Glutaminglutamine 0,05 Gew.-%0.05% by weight Sojaextrakt GSoya extract G 10 Gew.-%10% by weight

Rezept 6: Isoflavon-LiposomeRecipe 6: Isoflavone liposomes Sojaextrakt|30%Soy extract | 30% Wasser deminWater demin 40%40% Lipiddispersionlipid dispersion 30%30% durch Kavitator prozessieren.through cavitator process.

Claims (19)

1. Mittel zur Behandlung der Haut, dadurch gekennzeichnet, daß es als Wirkstoff Isoflavon enthält.1. A skin treatment agent, characterized in that it contains isoflavone as active ingredient. 2. Mittel nach Anspruch 1, dadurch gekennzeichnet, daß es Derivate des Isoflavons enthält.2. Means according to claim 1, characterized in that it contains derivatives of isoflavone. 3. Mittel nach Anspruch 2, dadurch gekennzeichnet, daß die Derivate Glykoside, Ether, Ester, Acetale des Isoflavons oder vom Isoflavon abgeleitete Säuren, Salze, Chinone, Acetale sind.3. Means according to claim 2, characterized in that the derivatives are glycosides, ethers, Esters, acetals of isoflavone or isoflavone-derived acids, salts, Quinones, acetals are. 4. Mittel nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß es mindestens 0,005 Gew.-% Isoflavon oder Isoflavonderivate enthält.4. Composition according to one of claims 1 to 3, characterized in that it contains at least 0.005% by weight Isoflavone or isoflavone derivatives. 5. Mittel nach Anspruch 4, dadurch gekennzeichnet, daß es 0,1 bis 0,005 Gew.-% Isoflavon oder Isoflavonderivate enthält.5. Means according to claim 4, characterized in that it contains 0.1 to 0.005% by weight of isoflavone or isoflavone derivatives. 6. Mittel nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß der Wirkstoff 4-Hydroxy-7-Glucose- Isoflavon ist.6. Composition according to one of claims 1 to 5, characterized in that the active ingredient is 4-hydroxy-7-glucose Isoflavone is. 7. Mittel nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß der Wirkstoff 5,7,4′Trihydroxy- Isoflavon ist. 7. Composition according to one of claims 1 to 5, characterized in that the active substance 5,7,4'trihydroxy Isoflavone is.   8. Mittel nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß der Wirkstoff 5,4′Dihydroxy, 7-Glucose-Isoflavon ist.8. Composition according to one of claims 1 to 5, characterized in that the active ingredient is 5,4'-dihydroxy, 7-glucose isoflavone. 9. Mittel nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß der Wirkstoff 5-Hydroxy 7,4′ Dimethoxy-Isoflavon ist.9. Composition according to one of claims 1 to 5, characterized in that the active ingredient is 5-hydroxy 7,4 ' Dimethoxy isoflavone is. 10. Mittel nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß der Wirkstoff 7,4′Dihydroxy- Isoflavon ist.10. Composition according to one of claims 1 to 5, characterized in that the active ingredient is 7,4'-dihydroxy- Isoflavone is. 11. Mittel nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß der Wirkstoff 5,7′Dihydroxy- 4′methoxy-Isoflavon ist.11. Composition according to one of claims 1 to 5, characterized in that the active substance 5,7'dihydroxy 4'methoxy isoflavone. 12. Mittel nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß der Wirkstoff 3′,4′,5,7- Tetrahydroxy-Isoflavon ist.12. Composition according to one of claims 1 to 5, characterized in that the active ingredient 3 ', 4', 5,7- Tetrahydroxy isoflavone is. 13. Mittel nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß der Wirkstoff 3′,4′,5-Trihydroxy- 7-methoxy-Isoflavon ist.13. Composition according to one of claims 1 to 5, characterized in that the active ingredient 3 ', 4', 5-trihydroxy 7-methoxy isoflavone. 14. Mittel nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß der Wirkstoff 3′,5,7-Trihydroxy- 4′-methoxy-Isoflavon ist.14. Composition according to one of claims 1 to 5, characterized in that the active ingredient 3 ', 5,7-trihydroxy 4'-methoxy isoflavone. 15. Mittel nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß der Wirkstoff 3′,5,7-Trihydroxy- 4′,5′,6-trimethoxy-Isoflavon ist.15. Composition according to one of claims 1 to 5, characterized in that the active ingredient 3 ', 5,7-trihydroxy 4 ', 5', 6-trimethoxy isoflavone. 16. Mittel nach einem der Ansprüche 1 bis 15, dadurch gekennzeichnet, daß es zusätzlich Sterole enthält. 16. Composition according to one of claims 1 to 15, characterized in that it additionally contains sterols.   17. Anwendung des Mittels nach einem der Ansprüche 1 bis 16 zur medizinischen oder kosmetischen Behandlung der Haut gegen Couperose, Besenreisern, Melanomen, Alopecie, Akne, Fetthaut und Pigmentflecken.17. Application of the agent according to one of claims 1 to 16 for medical or cosmetic treatment of the skin against couperose, spider veins, Melanoma, alopecia, acne, greasy skin and pigmentation marks. 18. Verwendung der Mittels nach einem der Ansprüche 1 bis 17 als Haarwuchsmittel.18. Use of the agent according to any one of claims 1 to 17 as a hair restorer. 19. Verwendung des Mittels nach einem der Ansprüche 1 bis 17 als Radikalfänger.19. Use of the agent according to one of claims 1 to 17 as radical scavenger.
DE4432947A 1994-09-16 1994-09-16 Agent for the treatment of the skin and its use Revoked DE4432947C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE4432947A DE4432947C2 (en) 1994-09-16 1994-09-16 Agent for the treatment of the skin and its use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4432947A DE4432947C2 (en) 1994-09-16 1994-09-16 Agent for the treatment of the skin and its use

Publications (2)

Publication Number Publication Date
DE4432947A1 true DE4432947A1 (en) 1996-03-21
DE4432947C2 DE4432947C2 (en) 1998-04-09

Family

ID=6528338

Family Applications (1)

Application Number Title Priority Date Filing Date
DE4432947A Revoked DE4432947C2 (en) 1994-09-16 1994-09-16 Agent for the treatment of the skin and its use

Country Status (1)

Country Link
DE (1) DE4432947C2 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046208A2 (en) * 1996-06-07 1997-12-11 Mt. Sinai School Of Medicine Of The City Of New York Genistein as a preventive against ultraviolet induced skin photodamage and cancer
WO1998008503A1 (en) * 1996-08-30 1998-03-05 Novogen Research Pty. Ltd. Therapeutic methods and compositions involving isoflavones
EP0829261A3 (en) * 1996-09-13 1998-04-01 Director General of Shikoku National Agricultural Experiment Station, Ministry of Agriculture, Forestry and Fisheries Composition comprising isoflavone or derivatives thereof for promoting fat-degradation in fat-cells
WO1998048790A1 (en) * 1997-04-28 1998-11-05 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
DE19742025A1 (en) * 1997-09-24 1999-03-25 Beiersdorf Ag Use of flavone or flavanone derivatives to treat or prevent undesirable skin pigmentation
EP0998262A4 (en) * 1997-06-11 2000-05-10 Sherwood L Gorbach Isoflavonoids for treatment and prevention of aging skin and wrinkles
US6093411A (en) * 1998-03-16 2000-07-25 The Procter & Gamble Company Compositions for regulating skin appearance
EP1041964A1 (en) * 1998-09-10 2000-10-11 Avon Products, Inc. Method and compositions for reducing dermatological aging and for reducing bruising
EP1047420A1 (en) † 1998-01-20 2000-11-02 HANDELMAN, Joseph H. Modulation of hair growth
EP1049451A1 (en) * 1997-12-24 2000-11-08 Novogen Research Pty. Ltd. Compositions and method for protecting skin from uv induced immunosuppression and skin damage
EP1063990A1 (en) * 1998-03-26 2001-01-03 Novogen Research Pty. Ltd. Therapy of estrogen-associated disorders
WO2001017986A1 (en) * 1999-09-06 2001-03-15 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
FR2811562A1 (en) * 2000-07-13 2002-01-18 Oreal COMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA AND AN ISOFLAVONOID
EP1205179A1 (en) * 2000-11-10 2002-05-15 L'oreal Cosmetic composition comprising an aminophenol derivative and an isoflavonoid
WO2002047631A1 (en) * 2000-12-15 2002-06-20 L'oreal Composition, in particular cosmetic, containing 7-hydroxy dhea and/or 7-keto dhea and at least an isoflavonoid
EP1234572A1 (en) 2001-02-26 2002-08-28 Mibelle AG Cosmetics Skin treatment compositions containing isoflavone aglycones
DE10114305A1 (en) * 2001-03-23 2002-09-26 Beiersdorf Ag Reducing sebum production using cosmetic or dermatological preparations containing isoflavones, useful for e.g. eliminating comedones or treating greasy hair or dandruff
DE10121375A1 (en) * 2001-05-02 2002-11-07 Beiersdorf Ag Use of isoflavonoids in cosmetic or dermatological preparations for the prophylaxis and treatment of sensitive skin
WO2004022027A1 (en) * 2002-09-04 2004-03-18 Omega Pharma Nv Anti-wrinkles cosmetic compositions
US6987098B2 (en) 1992-05-19 2006-01-17 Novogen Research Pty. Ltd. Health supplement
US6994864B2 (en) 2000-12-15 2006-02-07 L'oreal Composition containing 7-hydroxy DHEA and/or 7-keto DHEA and at least a carotenoid
US7033621B1 (en) 1997-04-28 2006-04-25 Novogen, Inc. Isoflavone compositions produced from legumes
US7056952B1 (en) 1999-04-30 2006-06-06 G.J. Consultants Pty. Ltd. Isoflavone metabolites
EP1700617A1 (en) * 2005-03-02 2006-09-13 Dr. Kurt Wolff GmbH & Co. KG Composition for activating the hair follicules and use thereof
AU2004224982B2 (en) * 1996-08-30 2007-09-13 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflavones
US7312344B2 (en) 2001-03-08 2007-12-25 Novogen Research Pty Limited Dimeric isoflavones
JP2009057379A (en) * 2007-08-07 2009-03-19 Calbee Foods Co Ltd New isoflavone compound
EP0907351B2 (en) † 1996-03-29 2012-04-18 Keyvest GmbH Cosmetic or cosmetic preparation for smoothing and tightening the skin in the case of subcutaneous fatty tissue problems, particularly cellulite
WO2012143856A1 (en) 2011-04-19 2012-10-26 Laboratoires Inneov Use of a combination of carotenoid, phytoestrogen and vitamin c for the prevention and/or treatment of pigmentation disorders
WO2012143857A1 (en) 2011-04-19 2012-10-26 Laboratoires Inneov Combination of carotenoid, phytooestrogen and vitamin c for moisturizing the skin

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19634206C2 (en) * 1996-08-26 2000-01-20 Ludwig Reinke Skin care products, in particular for aging skin
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CA 100:108983 der JP-Anmeldung 82/107775 vom 23. Juni 1982 *
CA 111:219115 der JP-Anmeldung 87/255292 vom 9. Oktober 1987 *
CA 120:307102 der JP-Anmeldung 92/200354 vom 02. Juli 1992 *

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987098B2 (en) 1992-05-19 2006-01-17 Novogen Research Pty. Ltd. Health supplement
US7045155B2 (en) 1992-05-19 2006-05-16 Novogen Research Pty Ltd. Dietary supplements comprising soy hypocotyls containing at least one isoflavone
USRE40792E1 (en) 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
EP0907351B2 (en) † 1996-03-29 2012-04-18 Keyvest GmbH Cosmetic or cosmetic preparation for smoothing and tightening the skin in the case of subcutaneous fatty tissue problems, particularly cellulite
WO1997046208A3 (en) * 1996-06-07 1998-02-19 Sinai School Medicine Genistein as a preventive against ultraviolet induced skin photodamage and cancer
WO1997046208A2 (en) * 1996-06-07 1997-12-11 Mt. Sinai School Of Medicine Of The City Of New York Genistein as a preventive against ultraviolet induced skin photodamage and cancer
AU2004224982B2 (en) * 1996-08-30 2007-09-13 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflavones
GB2331015B (en) * 1996-08-30 2001-05-09 Novogen Res Pty Ltd Therapeutic methods and compositions involving isoflavones
EP1927352A3 (en) * 1996-08-30 2008-11-19 Novogen Research Pty. Ltd. Therapeutic methods and compositions involving isoflavones
US6649648B1 (en) 1996-08-30 2003-11-18 Novogen Research Pty Limited Therapeutic methods and compositions involving isoflavones
WO1998008503A1 (en) * 1996-08-30 1998-03-05 Novogen Research Pty. Ltd. Therapeutic methods and compositions involving isoflavones
US7202273B2 (en) 1996-08-30 2007-04-10 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflavones
EP1927352A2 (en) * 1996-08-30 2008-06-04 Novogen Research Pty. Ltd. Therapeutic methods and compositions involving isoflavones
GB2331015A (en) * 1996-08-30 1999-05-12 Novogen Res Pty Ltd Therapeutic methods and compositions involving isoflavones
EP0829261A3 (en) * 1996-09-13 1998-04-01 Director General of Shikoku National Agricultural Experiment Station, Ministry of Agriculture, Forestry and Fisheries Composition comprising isoflavone or derivatives thereof for promoting fat-degradation in fat-cells
WO1998048790A1 (en) * 1997-04-28 1998-11-05 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
US7033621B1 (en) 1997-04-28 2006-04-25 Novogen, Inc. Isoflavone compositions produced from legumes
EP0998262A4 (en) * 1997-06-11 2000-05-10 Sherwood L Gorbach Isoflavonoids for treatment and prevention of aging skin and wrinkles
EP0998262A1 (en) * 1997-06-11 2000-05-10 Sherwood L. Gorbach Isoflavonoids for treatment and prevention of aging skin and wrinkles
DE19742025A1 (en) * 1997-09-24 1999-03-25 Beiersdorf Ag Use of flavone or flavanone derivatives to treat or prevent undesirable skin pigmentation
EP1049451A1 (en) * 1997-12-24 2000-11-08 Novogen Research Pty. Ltd. Compositions and method for protecting skin from uv induced immunosuppression and skin damage
EP1049451A4 (en) * 1997-12-24 2001-04-11 Novogen Res Pty Ltd Compositions and method for protecting skin from uv induced immunosuppression and skin damage
EP1047420B2 (en) † 1998-01-20 2011-08-24 The Gillette Company Modulation of hair growth
EP1047420A1 (en) † 1998-01-20 2000-11-02 HANDELMAN, Joseph H. Modulation of hair growth
US6093411A (en) * 1998-03-16 2000-07-25 The Procter & Gamble Company Compositions for regulating skin appearance
EP1063990A1 (en) * 1998-03-26 2001-01-03 Novogen Research Pty. Ltd. Therapy of estrogen-associated disorders
EP1063990A4 (en) * 1998-03-26 2003-01-02 Novogen Res Pty Ltd Therapy of estrogen-associated disorders
EP1041964A4 (en) * 1998-09-10 2003-09-03 Avon Prod Inc Method and compositions for reducing dermatological aging and for reducing bruising
EP1041964A1 (en) * 1998-09-10 2000-10-11 Avon Products, Inc. Method and compositions for reducing dermatological aging and for reducing bruising
US7056952B1 (en) 1999-04-30 2006-06-06 G.J. Consultants Pty. Ltd. Isoflavone metabolites
JP2003508526A (en) * 1999-09-06 2003-03-04 ノボゲン リサーチ ピーティーワイ リミテッド Compositions and therapeutic methods comprising isoflavones and analogs thereof
WO2001017986A1 (en) * 1999-09-06 2001-03-15 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US7488494B2 (en) 1999-09-06 2009-02-10 Novogen Research Pty Ltd. Compositions and therapeutic methods involving isoflavones and analogues thereof
FR2811562A1 (en) * 2000-07-13 2002-01-18 Oreal COMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA AND AN ISOFLAVONOID
WO2002005764A1 (en) * 2000-07-13 2002-01-24 L'oreal Composition, in particular cosmetic, containing dhea and isoflavonoid
EP1205179A1 (en) * 2000-11-10 2002-05-15 L'oreal Cosmetic composition comprising an aminophenol derivative and an isoflavonoid
US6994864B2 (en) 2000-12-15 2006-02-07 L'oreal Composition containing 7-hydroxy DHEA and/or 7-keto DHEA and at least a carotenoid
FR2818148A1 (en) * 2000-12-15 2002-06-21 Oreal COMPOSITION, IN PARTICULAR COSMETIC, CONTAINING 7-HYDROXY DHEA AND / OR 7-CETO DHEA AND AT LEAST ONE ISOFLAVONOID
US6852326B2 (en) 2000-12-15 2005-02-08 L'oreal Composition, in particular cosmetic, containing 7-hydroxy DHEA and/or 7-keto DHEA and at least an isoflavonoid
WO2002047631A1 (en) * 2000-12-15 2002-06-20 L'oreal Composition, in particular cosmetic, containing 7-hydroxy dhea and/or 7-keto dhea and at least an isoflavonoid
EP1234572A1 (en) 2001-02-26 2002-08-28 Mibelle AG Cosmetics Skin treatment compositions containing isoflavone aglycones
US7312344B2 (en) 2001-03-08 2007-12-25 Novogen Research Pty Limited Dimeric isoflavones
WO2002076409A3 (en) * 2001-03-23 2003-04-24 Beiersdorf Ag Cosmetic and dermatological preparations comprising an isoflavone content
DE10114305A1 (en) * 2001-03-23 2002-09-26 Beiersdorf Ag Reducing sebum production using cosmetic or dermatological preparations containing isoflavones, useful for e.g. eliminating comedones or treating greasy hair or dandruff
WO2002076409A2 (en) * 2001-03-23 2002-10-03 Beiersdorf Ag Cosmetic and dermatological preparations comprising an isoflavone content
DE10121375A1 (en) * 2001-05-02 2002-11-07 Beiersdorf Ag Use of isoflavonoids in cosmetic or dermatological preparations for the prophylaxis and treatment of sensitive skin
WO2002087517A2 (en) * 2001-05-02 2002-11-07 Beiersdorf Ag Use of isoflavonoids in cosmetic or dermatological preparations for the prophylaxis or treatment of sensitive skin
WO2002087517A3 (en) * 2001-05-02 2003-02-27 Beiersdorf Ag Use of isoflavonoids in cosmetic or dermatological preparations for the prophylaxis or treatment of sensitive skin
DE10121375B4 (en) * 2001-05-02 2014-01-16 Beiersdorf Ag Use of isoflavonoids in cosmetic or dermatological preparations for the prophylaxis and treatment of sensitive skin
WO2004022027A1 (en) * 2002-09-04 2004-03-18 Omega Pharma Nv Anti-wrinkles cosmetic compositions
EP1700617A1 (en) * 2005-03-02 2006-09-13 Dr. Kurt Wolff GmbH & Co. KG Composition for activating the hair follicules and use thereof
JP2009057379A (en) * 2007-08-07 2009-03-19 Calbee Foods Co Ltd New isoflavone compound
WO2012143856A1 (en) 2011-04-19 2012-10-26 Laboratoires Inneov Use of a combination of carotenoid, phytoestrogen and vitamin c for the prevention and/or treatment of pigmentation disorders
WO2012143857A1 (en) 2011-04-19 2012-10-26 Laboratoires Inneov Combination of carotenoid, phytooestrogen and vitamin c for moisturizing the skin

Also Published As

Publication number Publication date
DE4432947C2 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
DE4432947C2 (en) Agent for the treatment of the skin and its use
DE69914726T2 (en) COMPOSITION FOR REGULATING THE SKIN APPEARANCE
DE60022756T2 (en) SKIN CARE COMPOSITION
DE19922287B4 (en) Use of flavonoid esters in cosmetics
DE60022758T2 (en) SKIN CARE COMPOSITION
DE10035735C2 (en) Hair tonic to prevent or treat hair loss
DE69913035T9 (en) Cosmetic composition with antiradical synergistic effect
EP0799022A1 (en) Use of flavonoids for protecting unstable cosmetic active substances and constituents in cosmetic and dermatological formulations
DE60125823T2 (en) COMPOSITION, ESPECIALLY COSMETIC COMPOSITION, WITH 7-HYDROXY-DHEA AND / OR 7-KETO-DHEA AND AT LEAST ONE ISOFLAVONOID
KR102503410B1 (en) Compositions Containing Phenolic Compounds with Synergistic Antioxidant Benefits
DE60035059T2 (en) MEDIUM TO IMPROVE SKIN TEXTURE
JPH06336419A (en) External agent for skin
EP1430933A2 (en) Cosmetic and pharmaceutical compositions comprising steroid sulfatase inhibitors and their use for the reduction of hair loss
JPS6061513A (en) Cosmetic
EP4221675A1 (en) Composition for treating hair, scalp and skin
EP1327438A1 (en) Cosmetic composition and use of same
DE60219432T2 (en) TOPICAL SOLUTION CONTAINING ISOFLAVON AGLYKON
JPH0745421B2 (en) Method for preventing discoloration of polyphenol
JPH082819B2 (en) Method for preventing discoloration of polyphenol
JP2006008537A (en) External preparation for skin
EP2162115B1 (en) Advanced glycation end products as active ingredients
DE60306584T2 (en) Use of a 7-oxidized DHEA derivative for the treatment of dry skin
KR100346856B1 (en) External preparation for skin
DE60208342T2 (en) PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR THE PROTECTION OF THE SKIN AGAINST SUNSHAVIOR DAMAGE
EP1338269B1 (en) Use of creatinine and/or creatinine derivatives for whitening the skin and alleviating of pigmentation disorders

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8363 Opposition against the patent
8331 Complete revocation